On December 15, Baiji Shenzhou, a biotechnology company, was listed on the science and innovation board. It is also the first biotechnology company in the world to be listed on Nasdaq, Hong Kong Stock Exchange and Shanghai Stock Exchange. The issue price is 192.60 yuan and the number of shares issued is 115 million. Baiji Shenzhou opened today at 176.96 yuan, down more than 8%. As of noon closing, Baiji Shenzhou's share price was 168 yuan, down 12.77%.
Baiji Shenzhou is a global and commercial biotechnology company focusing on research, development, production and commercialization of innovative drugs. As of November 4, 2021, there were 48 commercial products and clinical candidate drugs in Baiji Shenzhou. Among them, three independently developed drugs are in the commercialization stage, namely, Btk small molecule inhibitor brukinsa (zanubrutinib capsule), anti-PD-1 monoclonal antibody baizean (tirelizumab injection), and PARP inhibitor baihuize (pamiparib capsule). Eight independently developed candidate drugs are in the clinical research stage, 37 cooperative products in clinical or commercial stage.
In the listing announcement, Baiji Shenzhou once disclosed that the R & D, production and commercialization of new drugs is a process with large investment, long cycle and high risk. It continues to invest in many links such as early drug discovery, preclinical research, clinical development, regulatory review, production and commercialization promotion. As of June 30, 2021, the accumulated undistributed profit of Baiji Shenzhou was -30.076 billion yuan.
(Beijing News)
